Terms ending in 2043
Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,516,349 | Methods and Systems for Manufacturing Viral Vectors In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,421,315 | CLL-1 Targeted Immunotherapies In force · High confidence | Inhibrx Biosciences, Inc. | In force | High confidence | |
| US 12,516,129 | Dimerizing Agent Regulated Immunoreceptor Complexes In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,590,136 | Engineered T Cells In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,552,855 | CD33 Targeted Immunotherapies In force · High confidence | Inhibrx Biosciences, Inc. | In force | High confidence | |
| US 12,545,746 | Anti-Bcma Car Antibodies, Conjugates, and Methods of Use In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 12,752,006 | Bcma Chimeric Antigen Receptors In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,577,547 | PDCD-1 Homing Endonuclease Variants In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.